Sangamo Therapeutics - M&A Summary and Business Overview

Life ScienceCompany

Sangamo Therapeutics M&A Summary

Sangamo Therapeutics has acquired 4 companies. A total of 1 acquisition came from private equity firms.

Sangamo Therapeutics’ largest acquisition to date was in 2018, when it acquired TxCell S.A. for $81M. Sangamo Therapeutics has acquired in 1 US state, and 3 countries. The Company’s most targeted sectors include life science (100%).

Sangamo Therapeutics Business Overview

Where is Sangamo Therapeutics headquartered?

Sangamo Therapeutics is headquartered in Richmond, California.

What is Sangamo Therapeutics’ revenue?

Sangamo Therapeutics disclosed revenue of 176M USD for 2023 and 111M USD for 2022.

How many employees does Sangamo Therapeutics have?

Sangamo Therapeutics has 405 employees.

What sector is Sangamo Therapeutics in?

Sangamo Therapeutics is a life science company.

When was Sangamo Therapeutics founded?

Sangamo Therapeutics was founded in 1995.

M&A Summary

  • M&A Total Activity4
    • M&A Buy Activity4
  • Total Sectors Invested 1
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 2
  • M&A Advisors 1

Sangamo Therapeutics

Sangamo Therapeutics, Inc.

501 Canal Boulevard,
Richmond, California 94804
United States,
(510) 970-6000
www.sangamo.com

Sangamo Therapeutics is a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company’s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. Sangamo Therapeutics was founded in 1995 and is based in Richmond, California.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.0/yr) # 4 - - - - - 4
vol $121M $121M
Sell (0.0/yr) # - - - - - - 0
  4

Most Recent M&A

Company Date Value Type
TxCell S.A. 2018-07-23 81M EUR Add-on Acquisition
Valbonne, France · www.txcell.com
Ceregene, Inc. 2013-08-26 - Add-on Acquisition
San Diego, California · www.ceregene.com/
Edwards Lifesciences Corp. - Angiogenesis Program 2006-12-04 - Divestiture
Irvine, California
Gendaq Ltd. 2001-05-30 40M USD Add-on Acquisition
London, United Kingdom
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 4 (100%) 121M (100%) - -
Total 4 $121M - -

By Geo

State/Country Buy Value Sell Value
United States 2 - - -
  California 2 - - -
France 1 81M - -
United Kingdom 1 40M - -
Domestic 2 (50%) - - -
Cross-border 2 (50%) 121M (100%) - -
Total 4 $121M - -

Top M&A Advisors

Financial Deals
Alantra Partners, S.A. - Investment Bank
 1

Deal Values

buy # Total
< $100M 2 $121M
TOTAL $121M
Largest TxCell S.A.
$81M (2018-07-23)

M&A Connections

Deals
Acquired from
Investor(s)
25%
1 (25%)
Strategic(s)
25%
1 (25%)

Company Summary

SECTOR

Life Science

Revenue

176   59% 2023
111   0% 2022
111   6% 2021
118   16% 2020
102   22% 2019
84   128% 2018
37   95% 2017
19   53% 2016
40   14% 2015
46   92% 2014
24   15% 2013
21   2012
(millions of USD) Show More Show Less

Employees

405

Established

1995

Public

NASDAQ: SGMO

Former Name

Sangamo BioSciences, Inc.

 Subscribe to unlock this and 206,153
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for Sangamo Therapeutics

California Companies , Life Science Companies , United States Companies , California Life Science Companies , California Life Science with Acquisitions , California Life Science with Divestitures

Related Lists for California Companies

Largest California Companies , Acquisitive California Companies , Recently Acquired California Companies , Recently Sold California Companies , Private California Companies , Public California Companies , Acquired California Companies , PE Backed California Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies

Related Lists for United States Companies

Largest United States Companies , Acquisitive United States Companies , Recently Acquired United States Companies , Recently Sold United States Companies , Private United States Companies , Public United States Companies , Acquired United States Companies , PE Backed United States Companies
Mergr

Product

Company

Legal